How were NPS Pharmaceuticals' earnings last quarter?

NPS Pharmaceuticals Inc (NASDAQ:NPSP) announced its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company earned $66.70 million during the quarter, compared to the consensus estimate of $69.30 million.

What other stocks do shareholders of NPS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NPS Pharmaceuticals investors own include Gilead Sciences (GILD) , General Electric (ge) , Intercept Pharmaceuticals (ICPT) , Pharmacyclics (PCYC) , Pfizer (PFE) , Alkermes (ALKS) , 3D Systems (DDD) , FireEye (FEYE) and GW Pharmaceuticals (GWPH) .

NASDAQ:NPSP

NPS Pharmaceuticals (NPSP) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free NPSP Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get NPS Pharmaceuticals alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About NPS Pharmaceuticals Stock (NASDAQ:NPSP)

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

NPSP Stock News Headlines

November 14, 2023 | forbes.com

Arena Pharmaceuticals

October 18, 2023 | investing.com

NPSP Historical Data

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 31, 2023 | thestreet.com

NPS Stock Gaps Down On Today's Open (NPSP)

February 13, 2023 | msn.com

How to reclaim withdrawn but unclaimed amount from National Pension System (NPS) account

December 15, 2022 | msn.com

How much money is held under National Pension System (NPS): State-wise data here

October 6, 2022 | msn.com

NPS proposes systematic lump sum withdrawal plan for pensioners; invites suggestions till 19 October

September 21, 2022 | thestreet.com

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

September 9, 2022 | msn.com

NPS Calculator: Want Rs 75,000 monthly pension post retirement? Here’s how much you need to invest

July 18, 2022 | thestreet.com

Enzon and NPS Pharma Call Off Merger

June 28, 2022 | msn.com

NPS Pension Calculator: Now you can get Rs 2 lakh per month, here's how

May 4, 2022 | thestreet.com

Cramer's 'Mad Money' Recap: The Winning Formula

February 20, 2022 | forbes.com

Krispy Kreme Doughnuts (DNUT)

January 7, 2022 | thestreet.com

European Stocks Rebound as Pharma Deals Renew Confidence

October 26, 2021 | finance.yahoo.com

Celgene and NPS Pharmaceuticals Shares Surge on Positive FDA News

See More Headlines

Receive NPSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NPS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/18/2015
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:NPSP
CUSIP: 62936P10
CIK: 890465
Web: www.npsp.com
Phone: +1-908-4505300
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

NPSP Stock Analysis - Frequently Asked Questions

How were NPS Pharmaceuticals' earnings last quarter?: NPS Pharmaceuticals Inc (NASDAQ:NPSP) announced its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company earned $66.70 million during the quarter, compared to the consensus estimate of $69.30 million.
What other stocks do shareholders of NPS Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NPS Pharmaceuticals investors own include Gilead Sciences (GILD), General Electric (ge), Intercept Pharmaceuticals (ICPT), Pharmacyclics (PCYC), Pfizer (PFE), Alkermes (ALKS), 3D Systems (DDD), FireEye (FEYE) and GW Pharmaceuticals (GWPH).

This page (NASDAQ:NPSP) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NPS Pharmaceuticals (NPSP) Stock Price, News & Analysis

About NPS Pharmaceuticals Stock (NASDAQ:NPSP)

NPSP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

NPSP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info